Differences in cancer dynamics may explain why prostate screening has cut metastatic disease while breast screening has notBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5741 (Published 29 October 2015) Cite this as: BMJ 2015;351:h5741
View Full Text
- Susan Mayor
Differences in how specific types of cancer grow and metastasise may explain why screening has reduced the number of men found to have metastatic prostate cancer at the time of diagnosis but has had no effect on the proportion of women with metastatic breast cancer when first diagnosed, a new analysis claims.
The analysis, published in the New England Journal of Medicine,1 looked at trends in the number of women over 40 with metastatic breast cancer at first presentation using data from the US …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.